157
Views
6
CrossRef citations to date
0
Altmetric
REVIEW ARTICLE

Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists

Pages 229-234 | Received 20 Apr 2006, Accepted 25 Apr 2006, Published online: 12 Jul 2009
 

Abstract

Abatacept is a newly approved treatment for rheumatoid arthritis refractory to other agents. Abatacept is a fusion protein of the cytotoxic T‐lymphocyte antigen (CTLA) molecule and immunoglobulin (Ig) G1 that blocks CD28. Specifically, abatacept blocks the CD80 and CD86 ligands on the surface of antigen‐presenting cells that must interface with the T‐cell's CD28 receptor to activate T cells. Abatacept seems to be more immunosuppressive than tumor necrosis factor alpha blockers. The combination of abatacept and a tumor necrosis factor alpha blocking agent does not seem more effective than either agent alone. Because abatacept has the ability to suppress T‐cell function, it has the potential to be a treatment for psoriasis and other autoimmune conditions involving pathologic processes driven by T cells.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.